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1. Introduction 
Rectal cancer has in general been  a disease of the middle aged and 
elderly, such that the most patients  diagnosed with the disease are 
beyond 55 years of age. While only 2-10% of all rectal cancers in 
Western nations occur in young patients,  it has been reported to 
occur with a much greater incidence among young patients in South 
East Asia [1]. At the same time, a recent population based study in the 
United States has reported an increasing incidence of rectal cancer in 
the young adults [2].  A number of  recent epidemiologic studies have 
also highlighted such increase in the occurence of young-onset rectal 
cancer[3-7]. The  cut off  age or age group  for defining patients with 
young rectal cancer with respect to aggressive biology and survival 
statistics is not well defined. There are studies citing 35, 40, 45and 50 
years as the cut off ages with conflicting data with respect to poorer 
survival .In spite of its rising incidence, there are only a few studies on 
the prognosis and clinicopathologic features  young-onset rectal 
cancer. Furthermore, it has also been observed that the survival of 
younger patients with rectal cancer is poorer compared to older 
patients [8]. While most agree that younger patients are diagnosed at 
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an advanced stage of the disease as compared with the older patients 
[9-11], and with poorer differentiation [12] resulting in poorer survival, 
it has also been suggested that the tumours in younger patients are 
biologically different  to that in the older patients. Despite such 
differences in the tumor development and differentiation, patients with 
young-onset rectal cancer are currently being treated with similar 
procedure as later-onset ones and new treatment stratergies focusing 
on rectal cancer in young adults need to be developed [13,14In this 
regard, there have been conflicting data from studies of Western 
patients with some reports suggesting a poorer outcome for younger 
patients [15,16], while others indicate no difference in the stage-
specific oncologic outcomes between the young and older cohorts 
[17]. Therefore, in this thesis we present a systematic study of rectal 
cancer in young adults and survival outcomes in young rectal patients 
in the southern parts of India as compared to their older counterparts. 
The central goal of this work is to analyse the relative distribution and 
the clinicopathological profile  of rectal cancer across various age 
groups  especially among the young. At the same time, we analyze 
and compare the effectiveness of  treatments towards the outcomes 
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between the younger and older patients with the future goal of tailoring 
treatment strategies which could account for the differences in the 
biological features of rectal cancer in younger patients. 
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2. Review of Literature 
Colorectal Cancer (CRC) is a major cause of morbiditiy and mortality 
globally resulting in more than 500,000 deaths anually) [18].  More 
than 90% of the patients with CRC in the West are diagnosed post55 
years of age and  is hence considered primarily to be the disease of 
the elderly. Consequently, in the absence of  predisposing conditions 
like idiopathic inflammatory disease (IBD) or familial syndromes, 
screening programs for rectal cancer usually start at the age of 50 
years [19]. While the estimated incidence of rectal cancer in India 
(2.0–3.3 per 100,000 population in men and 1.4–2.4 per 100,000 in 
women) is much lower than Western countries (12.9–18.8 per 100,000 
in men and 6.9–8.6 per 100,000 in women in the United Kingdom) 
[20]; there have been speculations that there might be a high relative 
incidence of rectal cancer amongst young South-East Asian 
populations [21,22]. The Madras Metropolitan Tumour Registry 
(MMTR), a population based cancer registry in Chennai shows a  
crude incidence rate of   4.4 /1,00,000 for rectal cancer in males with 
an age specific rate of 4.8/1,00,000 during the year 2009-2010.  
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In a recent study involving 89 adult patients diagnosed with rectal 
cancer from North India, it was shown that the average age of 
presentation was found to be as low as 45 years [23]. Moreover, 
studies based on the hospital registry at the Christian Medical College, 
Vellore demonstrated that the relative incidence of  rectal cancer in 
the age group 40 years and younger can be as high as 35.5% [24].  
The same was observed in yet another study from Maulana Azad 
Medical college, New Delhi that focussed exclusively on rectal cancer 
in the age group from 10-25 years and reported 32 patients in this 
group with an incidence of 9.9% of the total colorectal cases 
registered [25]. 
Apart from the high occurence of young rectal cancer in India as 
reported above, the studies from CMC, Vellore [24] also suggested 
that the histopathological features of rectal tumours in young Indian 
patients under investigation were in agreement with similar studies in 
West. In their study, it was found that  young patients undergoing 
surgery had a higher chance  of receiving neoadjuvant therapy 
because of more advanced disease at presentation. Despite the 
possible downstaging effects of such therapy, young patients 
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undergoing surgery had a more advanced pathological T and N stage 
compared with the older group. The more advanced histopathology 
seen in young patients in this study are in accordance with several 
other studies involving western patients [26]. 
Another study from Tata Memorial Centre, further showed that the 
younger patients had higher stage at diagnosis with higher lymph 
node positivity and lower Disease Free Survival (DFS) [27]. They 
reported a significantly poorer stage-specific DFS with stage III 
disease in patients less than 40 years of age as compared to the older 
patients. Their findings concurred with those of Smith et al. [16] and 
Cusack et al. [15] and contradicted reports that attributed the poorer 
survival in younger patients to delays in presentation with no 
difference in stage-specific survival between old and young rectal 
cancer patients  [17, 28]. While the lack of screening and symtoms 
being overlooked that occurs in the case of younger patients is an 
important factor for the poorer survival statistics that has been seen in 
younger patients as compared to their older cohorts (3),(7N), this by 
itself does not explain the mucinous prevalence and poor 
differentiation in young rectal cancer and the fact that the tumour 
 
 
11 
 
location has been found to vary with patient age [29]. Furthermore, 
researchers have observed different time trends in the occurence for 
subsites and genders for rectal cancer in young adults suggesting 
different etiology in them as compared to  older patients [30, 31]. The 
current opinion regarding the relatively lower survival in younger 
patients is trending to the fact that while the biology of rectal cancer is 
different than in older patients, the diagnosis, screening and treatment 
strategies remain the same and are not tailored to account for these 
differences [32]. A better understanding of the biology of rectal cancer 
and etiological factors including gentics, histology, environmental 
factors and others, are necessary for developing effective diagnosis, 
screening and treatment strategies for rectal cancer in young adults.  
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2.1 Role of Genetics 
Despite several studies on the etilogical factors for rectal cancer in 
young adults, it is still unclear as to why young adults without a 
predisposing genetic abnormality develop rectal cancer? It has been 
reported previously that only a small minority can be linked to known 
predisposing syndromes, including familial polyposis syndromes, 
hereditary nonpolyposis colorectal cancer (HNPCC) or the Lynch 
syndrome, inflammatory bowel disease and more [2]. Moreover, 
established pathways of carcinogenesis in rectal cancer, such as 
chromosomal instability/aneuploidy, microsatellite instability, APC-
mutation, KRAS-mutation account only for small subsets of young 
patients [10, 33-35]. It may be hypothesized that even after exclusion 
of all patients with known HNPCC, a significant subset may possess 
undiagnosed HNPCC. If this were true, the incidence of microsatellite-
high (MSI-high) rectal cancer would be expected to be low. While a 
recent population based study of patients with rectal cancers revealed 
that  MSI-high status was found in only 2.2% of the cases; another 
study enriched with patients younger than 50 years found  MSI-high 
status in 17% of the tumours [28]. Several studies have also proposed 
 
 
13 
 
that chromosome 14 can play an important role in microsatellite stable 
colon carcinogenesis. As loss of chromosome 14 is more frequent in 
aggressive tumours and in young patients, this gene location is 
probably responsible in part for tumour aggressiveness and hereditary 
predisposition as reported by Mourra et al. [36]. Furthermore, Dunlop 
et al. [37] and Phillip et al. [38] also described  microsatellite instability 
as the cause for underlying tumour development in young CRC 
patients, regardless of HNPCC status [39]. The majority of these 
studies, however, suggest only a minor role of genetics towards the 
etiology for rectal cancer in the majority of the young patients.  
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2.2 Patterns in Histopathological Types 
Several studies have shown that the pattern of histopathological types 
of  rectal cancer differs in younger age patients as compared to their 
older cohorts. An article in Nature, reviewing the biology of cancer in 
young adults, reported that Mucinous adenocarcinoma occurs in 
nearly 50% of the cases for young  adults as compared to only 2–4% 
in older adults [32] and are associated with a worse prognosis. Griffin 
et al. [40] reported that ~28% of the lesions found in younger patients 
was constituted by mucinous tumours compared with ~5% for older 
cohorts. Further, mucinous adenocarcinoma showed higher 
frequencies of poor differentiation, advanced tumour stage, loss of 
MMR expression, and increased MUC2 expression compared with 
non-mucinous adenocarcinoma. The worse outcome in young patients 
has been attributed to the high percentage of this histologic subtype 
and of poorly differentiated tumours found in the age category [41].  
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2.2 Impact of Environmental Factors 
It is thought that environmental factors, especially dietary habits, can 
contribute to the increasing incidence and geographic distribution of 
rectal cancer. An empirical proof that has been provided for this is the 
westernization of the diet in Japan, which following 15 years of 
changed dietary behaviourhas become a high-risk country for CRC[2]. 
Similar observations have also been made on  Japanese immigrants 
to the United Staes [8] who adopted American culinary habits.  
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3. Modalities in the Treatment of Rectal Cancer 
3.1 Work up 
The standard work up for rectal cancer entails a history, physical 
examination, complete blood cell count, liver and renal function 
studies, as well as carcinoembryonic antigen (CEA) evaluation. High 
CEA levels are linked with poorchances of survival and indicate as to 
whether follow-up CEA determinations wouldbe useful. A careful rectal 
examination by an experienced examiner is an essential part of the 
pretherapy evaluation in determining distance of the tumour from the 
anal verge or from the dentate line, involvement of the anal sphincter, 
amount of circumferential involvement, clinical fixation, sphincter tone, 
and has not been replaced by imaging studies or endoscopy. 
Colonoscopy or barium enema to evaluate the remainder of the large 
bowel is essential (if the patient is not obstructed) to rule out 
synchronous tumours or the presence of polyp syndromes. 
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3.2 Histopathology 
The commonest histological type of rectal cancer is adenocarcinoma. 
Other histology types like squamous cell carcinoma, melanoma, 
neuroendocrine carcinoma, GIST were excluded. Among the 
adenocarcinomas, numerous histologic types of CRCs carry specific 
independent prognostic significance. For example, signet ring 
carcinomas are characterized by more than 50% of cells 
demonstrating the signet ring cell type morphology in which 
intracellular mucin accumulation displaces the nuclei and cytoplasm 
toward the cellular periphery. This histology carries an adverse 
prognosis [43]. The prognostic significance of the finding of mucinous 
carcinoma (more than 50% mucinous component) remains 
contentious. Although some reports list mucinous type as an adverse 
histology, this observation has not been consistent.  
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3.3 Clinicopathological Staging 
Standard clinicopathological staging is the best indicator of prognosis 
for patients with rectal cancer. For rectal cancer, it is increasingly 
common to use clinical staging and imaging in combination as the 
basis for the decision for neoadjuvant chemoradiation therapy. 
Therefore, the accuracy of that initial staging is critically important, 
both for management and for prognosis. 
3.3.1 AJCC 7th edition staging and stage groupings 
Patients  have both a clinical (preoperative) staging, which may define 
the use of neoadjuvant therapy, and a postoperative surgical stage 
[44]. However,  the initial therapy with radiation and chemotherapy can 
produce substantial down-staging (approximately 15% of patients will 
have a pathological complete response), and that subsequent therapy 
should be based on the initial T and N staging determination. Even 
with a  good tumour response locally in a patient who receives 
preoperative radiation and chemotherapy, postoperative 
chemotherapy should be given irrespective of the surgical pathology 
result. Until the data demonstrate otherwise, the plan for postoperative 
chemotherapy should be carried out even in the setting of a 
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pathological complete response. The major change that has occurred 
in the newest version of the staging system is the acknowledgment 
that both the T stage and the N stage have independent prognostic 
importance for local control, disease-free survival, and overall survival 
[25, 27]. Thus, for N0 and N1 patients viewed separately, the extent of 
the primary tumour in the rectum is of additional prognostic 
importance. Patients with T1-2N1 tumours have a relatively favorable 
prognosis and an outcome superior to that of other stage III patients. 
In fact, patients with T3N0M0 disease (stage II) have outcomes 
slightly inferior to those with T1-2N1M0, demonstrating the 
Table 1: AJCC7 Staging System for Colorectal Cancer [44] 
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independent prognostic importance of T stage. Although, at one level 
staging is very straightforward, the actuality of proper staging is much 
more difficult as it relies on multiple quality control issues that can 
mislead the clinician regarding proper therapy.  The vital components 
of staging are- 
 Experienced clinical staging 
 Quality in terms of imaging for T stage  , Nodal (N) stage  , 
Mesorectal fascia 
 Pathologic asseessment in terms of completeness and grade of 
Total Mesorectal Excision(TME), nodal yield, Circumferential 
radial margin(CRM) 
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3.4 Treatment of Rectal Cancer at Cancer Institute (WIA). 
3.4.1 Neoadjuvant Therapy 
Neoadjuvant therapy consisted of 2 cycles of intravenous 5 
fluorouracil at a dose 325mg/m2/day for 5 days (concurrently with 
radiation) and 1 cycle of Mitomycin C at a dose 6 mg/sq.m for 1 day 
(concurrently with radiation). External beam irradiation was 
administered up to a total dose of 5000 cGy (25 fractions, 200 cGy per 
fraction) administered by a four field box technique over a period of 
five weeks. The field included the tumour site within the pelvis as well 
as the lymphatic draining area reaching up to the L-5 to S-1 superiorly 
and the ischial tuberosities inferiorly. Laterally, the radiation field 
extended 1.5 cm beyond the bony pelvis. On the posterior aspect, the 
radiation encompassed the entire sacrum. 
 
3.4.2 Response to Treatment 
Patients were restaged at  four weeks after completion of NCRT to 
evaluate tumour response. Tumour response assessment consisted of 
similar radiologic and clinical studies used at initial staging. Clinical 
response to neoadjuvant chemoradiation was judged on surface area 
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of abnormality (tumour size) and intramural involvement (induration). 
Clinical response was defined as per following: 
 Complete: No residual tumour, no surface abnormality, no 
induration. 
 Partial:  more than 25% reduction in surface abnormality and 
induration. 
 Stable: No change in surface abnormality and induration. 
 Progression:  progression of disaese local/syatemic during 
neoadjuvant treatment 
3.4.3 Surgery 
Surgery was performed at 4 to 6 weeks after completion of NCRT. 
Surgery consisted of a total mesorectal excision (TME) based 
resection, either abdominoperineal resection or low anterior resection 
with en bloc resection of any adjacent organ involvement. Lymph 
nodes up to the origin of the inferior mesenteric artery are harvested. 
 
3.4.4  Pathologic assessment  
All the surgical specimens were fixed in 10% (by volume) formalin and 
routinely processed for paraffin embedding. Lymph nodes were 
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retrieved via gross examination and manual palpation. Patients were 
staged according to the American Joint Committee on Cancer 
guidelines (AJCC) [42]. Pathology reports included tumour size in cm, 
histology type, pathology stage, total number of regional lymph nodes 
present in the resected specimen, and number of lymph nodes with 
cancerous cells, and circumferential radial margin (CRM) and proximal 
and distal margins. 
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4. Aims and Objectives 
The following are the aims and objectives of my thesis: 
a ) To determine the relative distribution and the clinicopathological 
profile  of rectal cancer across various age groups  especially among 
the young  
b) To  study the influence of clinical ,histological and treatment related 
factors on survival  
c) To determine if possible any age cutoff  defining  young rectal 
cancer which would show a survival difference  over the older cohort . 
 
Selection Criteria 
A) Inclusion criteria - All cases diagnosed with Carcinoma rectum from 
1995 to 2007 
B) Exclusion criteria – Histological types of tumour such as carcinoid, 
gastrointestinal, stromal and neuroendocrine tumours, melanoma, 
squamous cell carcinoma were excluded. 
Patients with Familial Adenomatous Polyposis or those with other 
confirmed familial carcinoma syndromes were excluded from the 
study. 
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5. Materials and Methods 
A retrospective study of 552 patients, presenting to the Department of 
Surgical Oncology at Cancer Institute (WIA), Adyar, Chennai, India 
and registered in the tumour registry at the Institute between January 
1998  and December 2007 was done.  Only patients with histologically 
proven primary rectal adenocarcinoma were included, as defined as 
tumour involvement within 15 cm of the anal verge on digital rectal 
examination ⁄ colonoscopy and ⁄ or  CT imaging. The tumor location  
was classified  as follows: low rectum (0 to 6 cm from the anal verge), 
mid rectum (> 6 to 10 cm), and high rectum (more than 10 cm). 
Demographic data, presenting symptoms and their duration, 
pathological features of the tumour, tumour localization, histological 
data, pre-operative carcinoembryonic antigen (CEA) level, treatment 
modalities and survival data were retrospectively recorded and were 
analyzed. 
Tumor staging was as per the AJCC standards performed at the same 
time period as the treatment . Clinical stage was determined by 
preoperative imaging and endoscopy, including computer tomography 
(CT). Pathologic stage was based on the surgical resection specimen. 
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Chemotherapy regimen was 5-fluorouracil based. Surgical treatment 
was broadly categorized as abdominal perineal resection (APR), low 
anterior resection (LAR), which included all sphincter-preserving 
operations (i.e. coloprocto- or coloanal anastomosis), anterior 
resection and exented extenteration surgeries with multiorgan 
resections.  
Follow up was by direct communication with patients and their 
relatives in the out-patient clinic or by telephone or mail. Patients were 
considered lost to follow up if the patient had failed to present at an 
out-patient clinic, or could not be contacted by telephone or letter, 
after more than 3 years. During follow up, patients were assesed by 
history and physical examination, including digital rectal examination 
and CEA level every three months. A chest radiograph and trans-
abdominal ultrasound scan or computerized tomogram was 
undertaken at one year. Colonoscopy was done once in five years. 
The date and site of the first tumour recurrence was reviewed. 
Recurrences were categorized as local if they were perianastomotic or 
located in the pelvis, and as distant if they involved para-aortic nodes, 
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liver, lung, or other distant organs. Patients were followed to their date 
of death or their last contact in the OPD. 
 
Statistical Considerations 
The estimated Statistical analysis will be done with SPSS software. 
Clinical profile and other variables will be carefully documented. 
Follow up details will be entered. Statistical correlation for multivariate 
analysis will be done with the help of cox regression method. Data 
were entered into Excel 2008 (Microsoft Corporation, Redmond, WA) 
and analyzed with SPSS® (SPSS Inc., version 8.0, Chicago, IL). P ≤ 
0.05 was considered statistically significant. The chi-squared test for 
trends or Fisher’s exact test was used whenever required.  
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6. Results 
6.1 Demography of patients 
In our effort to analyze the 
clinicopathological data and survival 
outcomes across the age groups, 
we categorized for demographic 
stratification as patients into two 
groups - (1) less or equal to 40 and 
(2) more than 40 years. Also 
distribution patterns were studied 
across every 10 year age groups. Figure 1 shows the distribution of 
the 552 patients across the various 
age groups. 173 patients belonged 
to group 1 (less or equal to 40) thus 
constituting 31% of the study 
population. 13% were <30 and 52% 
were younger than 50. Thus more 
than 50% of our rectal cancers 
Fig. 1: Age distribution of patients studied 
Age Group (years) 
Fig. 2: Male to Female ratio of patients in 
each age group 
Age Group (years) 
1.73 
1.91  
2.5 
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patients are younger than 50 in 
contradiction to the western 
statistics. The reasons possibly 
being increased incidence of CRC in 
the young in our sample population 
and probably confounded by the fact 
that we have a demographically 
younger population compared to the 
West. The male/female ratio was statistically insignificant across age 
groups  with a p value of 0.198 (Fig. 2).While 12 patients in group 1 
had a family history of cancer as against 37 in group 2, the difference 
was insignificant with a p-value of 0.28 (Fig. 3). While familial 
colorectal syndromes like FAP and HNPCC were excluded from the 
Fig. 3: Family history of cancer in 1.5 of each 
age group1.57 
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study, also few cases of ulcerative colitis with later development of 
rectal cancer were excluded. Nevertheless, the absence of any 
significant history of colorectal or any other malignancies in first 
degree relatives of the patients with respect to the older cohorts 
indicates that most of the cancers are possibly of sporadic nature. The 
pattern of dietary habits vegetarian vs non-vegetarian diet was evenly 
distributed among the population (fig. 4a). Addiction (alcohol, smoking 
and chewing tobacco, or a combination of any) showed up as a 
moderately significant factor for difference between the two age 
groups with p-value of 0.029* (Fig. 4b). However, addiction was 
significantly higher in the older age group and is therefore clearly not a 
a. b. 
Fig. 4: Distribution of a) Dietary habits and b) Addition to alcohol, tobacco and others for patients in 
each age group 
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factor responsible for increasing incidences of young rectal cancer. In 
summary, we have not found any demographic factor to explain the 
increased incidence in sporadic rectal cancer among young patients 
as compared to that in older patients. 
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6.2 Clinical Features and Tumour Characteristics: 
Clinical features of patients assessed were duration of symptoms, 
presence of comorbid illness and bowel obstruction. Fig 5 shows a 
significant proportion of the patients in group 1 with duration of 
symptoms (rectal bleeding) more than 6 months compared to the older 
cohort. This may be possibly due to reluctance on the part of younger 
patients to consult physicians and may contribute to their advanced 
stage of presentation. The role of comorbidity that included pre-
existing conditions like ischemic heart disease, chronic renal disease, 
COPD, liver disease which could compound the postoperative 
morbidity was found to be significantly greater in the case of older 
patients, as expected. Obstruction of bowel presented itself with 
Figure 5: Contingency plots for normalized frequency of several clinical factors (comorbid, duration of symptoms, and 
obstruction) at the time of presentation 
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increasing incidence of 8.7% in 
young adults as compared to 
3.4% in their older cohorts with 
the difference showing a 
moderately strong statistical 
significance with a p-value of 
0.009*.Unlike left sided colonic 
cancers that have 
characteristically stenosing growth presenting with bowel obstruction, 
the rectum being voluminous due to its storage capacity rarely 
presents with bowel obstruction. The most common clinical symptom 
for rectal cancer is bleeding per rectum. Stenosing tumours presenting 
with bowel obstruction and hence requiring diversion colostomy before 
or during neoadjuvant treatment was found to be significantly higher in 
young adult patients. The presence of synchronous proximal polyps 
was found to be not statistically significant in the two age categories 
with a p-value of 0.175.  The mean distance of tumour from the anal 
verge was found to have a rising trend as evident in Fig 6 i.e. higher 
age further is the tumor from the anal verge .The median distance of 
Fig. 6: Mean distance from anal verge for the 
different age categories 
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tumor from the anal verge was 
4 cm across all age groups. 
Around 81.5% of the tumours 
were within 6 cm from the anal 
verge (distal rectal cancer), 
with incidence varying from 
85.5% in group 1 to 79.7% in 
group 2. The distance was 
categorized to three  levels:  ‘1’ for distance less than 6 cm,(low 
rectum) ‘2’ for values more than 6 up to  10 cm (mid-rectum); and ‘3’ 
for distances greater than 10 cm (high rectum) for analysis of 
statistical significance and yielded a p-value of 0.137 indicating no 
significance. The median CEA values at presentation/diagnosis are 
higher in the younger populations, though not statistically significant 
as shown in Fig. 7. Statistical studies for difference in the incidence of 
circumferential and fixed tumours among young and old patients 
showed an extremely strong significance with a p-value of less than 
0.0001*. 
Fig. 7: Median CEA values of patients in the different 
age categories 
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Circumferential and fixed 
tumours by merit of their 
infiltrative growth pattern 
and probably the duration 
involved in tumour 
progression are inherently 
more aggressive in 
behavior compared to the 
polypoidal non-circumferential growth. In fact, most of the young adult 
patients (~71%) had circumferential tumours as compared to the 50% 
incidence of circumferential tumours in the older cohorts (Fig. 8).  In 
addition to this, Fig. 9a shows that about 68.5% of the tumours in 
young adults are fixed compared to 46.7% in the older cohorts. To 
further understand the trend in fixed tumours with age we look at the 
Fig. 8: Contingency plots for normalized frequency of 
circumferential tumour 
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trend in four different age groups as in Fig. 9b and observe that the 
incidence of rectal cancer with fixed tumour is inversely related to the 
age of the patient.  The statistical study reveals a strong significance 
with a p-value of less than 0.0001* and lead us to conclude that the 
incidence of circumferential and fixed tumours are much higher in 
younger patients and suggests aggressive infiltrative growth pattern of 
rectal cancer in younger adults.  
  
Fig. 9: Contingency plots for normalized frequency of fixed tumour in the age categories a) less than and 
greater than 40 years old and b) for the categories < 30, 30–40, 40-50, >50 
 
 
37 
 
6.3 Grade of Tumour (Tumour Differentiation)  
The grade of the tumour (tumour differentiation) was compared across 
the age groups and has been summarized in Fig. 10. While the 
number of well differentiated tumors were 6 and 8% in groups 1 and 2 
respectively, the number of poorly-differentiated ones were   50% in 
group 1 as compared to 31.5% in older patients (group 2) showing  a 
high statistical significane with a p-value of less than 0.0005*. The 
findings here are in tune with several other reports of poorer tumour 
differentiation in younger adults.  The trends shown in Fig. 10 also 
indicates that the number of poorly-differentiated tumours is inversely 
proportional to patient age (p-0.0001*). 
  
Fig. 10: Contingency analysis for grade categorized by patient age group as a) < or > 40 years and 
b)<30, 30-45, 45-60 and > 60 categories 
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6.4 Histology 
Tumour histology was compared across the age groups and has been 
summarized in Fig. 11a. The histology was broadly categorized into 1) 
Adenocarcinoma, 2) Signet Type Ring, and 3) Others including 
Mucinous Adenocarcinoma. Conventional adenocarcinoma was 
predominant across both the age groups with higher proportions in the 
older cohort. Analysis of distribution of tumour histology gave a p-
value of <0.0001* indicating high statistical significance. The higher 
grade signet ring histology were in significantly higher proportions in 
the young as has been previously reported.  In order to gain additional 
insight we looked for statistical significance for incidence in each age 
Fig.11: Contingency analysis for histology categorized by patient age group 
a. b. 
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category (Fig 11b). Again we see that the incidences of 
adenocarcinoma was higher in older patients and was found to have a 
high statistical significance of less than 0.0001*. An interesting 
difference, however, has emerged in this study is that while the 
incidence of mucinous adenocarcinoma is uniform across the ages in 
patients younger than 50 years, the incidence of signet type ring is 
mostly restricted to patients less than 30 years of age. 
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6.5 Clinical Staging of Patients  
 The Fig.12 shows the normalized frequency comparison for the 
clinical T stage (cT) for the two age groups. Younger patients present 
with an overal higher cT stage than the older cohort with significance 
of p < 0.0001*. 26% of the young had cT4 stage compared to 10% in 
the old. While 58 of the 
552 cases had 
synchronous metastasis 
and their distribution 
among the young 
(12.7%) and old (9.5%) 
was satistically 
insignificant. 
For completeness, we 
note that,  during the period of study from 1998-2007, there were 779 
cases that had reported to the Out Patient Department of the Cancer 
Research Institute, but were not evaluated because of distant 
metastases or locally advanced stage of cancer. Of these, 185 
patients were less than 40 years as compared to 594 patients who 
Fig. 12: Contingency plot for the clinical T-stage of patients at 
presentation 
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were older than 40. If 
these cases were to be 
included to the 532 
cases that were 
evaluated during the 
same time period, 
23.2% of patients 
younger than 40 were 
diagonosed with distant 
metastases as compared to 22.6% patients in the older cohort.  Fig.13 
shows the contingency plot for this distribution and yields a statistically 
insignificant p-value of 0.825.  
  
Fig. 13: Contingency plot for patients diagnosed with distant 
metastases at presentation 
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6.6 Neoadjuvant Therapy and Clinical Response 
More patients in the younger cohort were directed to NACT and RT 
(Fig. 14a) due to higher clinical stage at diagnosis, as seen in the 
earlier section, compared to the old. This difference, however, on 
analysis was found not to be statistically significant (p=0.062). Fig. 
14b shows the contingency plots comparing the clinical response for 
patients undergoing neoadjuvant treatment in the age categories 
under study. The clinical response was classified as complete, partial, 
stable and progression. As seen in the figure;  
26 patients of the 385 patients who received NACT RT had clinical 
Fig. 14: Contingency plots for a) patients receiving neoadjuvant treatment and b) their clinical respons for the 
respective age categories  
a. 
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complete response; 7 in the younger group and 19 in the older cohort 
(NS). At the same time, disease progression was more frequent in the 
younger patients (13.1%) as compared to the older patients (6.3%). 
These differences in the overall clinical response to NACT and RT in 
the two groups yielded an insignificant p-value of 0.207. 
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6.7 Type of surgery and pathological staging 
The type of surgical treatment was broadly grouped as 
abdominoperineal resections (APR), sphincter preserving surgeries 
which would include low anterior resection (LAR) and anterior 
resection (AR) and others. As is seen in Fig.15 the most common 
surgery done was APR which is evident from the analysis of distance 
of tumor from the anal verge showing most tumors being within 5 cm. 
There is no statistical significance (p=0.473) in the type of surgery in 
the young and old in the two age groups.  
On analysis of the data with respect to the number of sphincter 
sparing surgeries, it is 
observed that sphincter 
preservation surgery was 
more commonly performed 
during the latter half of the 
study from 2003 – 2007 
compared to the initial five 
years. This is possibly due to 
Fig. 15: Contingency plots comparing types of surgery 
across age groups 
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the distal resection margin up to 1cm being oncologically safe, 
becoming acceptable in the last decade and with better available 
surgical techniques more sphincter preservation surgeries were 
possible with distal tumors. Among the patients who underwent 
surgery, 91 had straight surgery by virtue of higher tumors and early 
stage at presentation and 229 had surgery after neoadjuvant therapy. 
The pathological T and N stage for these two groups were analyzed 
separately. For patients undergoing direct surgery, Fig. 16 shows a 
significant higher pT stage in younger patients undergoing straight 
surgery (p-value =0.001*) and no statistical significance in the pN 
Fig. 16: Contingency plots of normalized frequency for a) the pathological T stage and,  b) the pathological N 
stage respectively for patients that underwent direct surgery 
a. b. 
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stage (p-value=0.88). 
Among patients who underwent surgery after downstaging (Fig. 17), 
the ypT stage among the groups was not significant (Fig. 17a), but the 
ypN stage assumed significance with a p value of 0.003*  (Fig.17b). 
However this was not reflected in the final AJCC staging with 5.2%, 
21.5%, 46.4% and 9.2% of the patients over 40 years categorized as 
stage I, II, III and  IV respectively and in comparison to 4.1%, 15.1%, 
53.4 and 11.0% in the younger group (Fig. 17c). While the distribution 
of patients as per the AJCC staging was similar in young and older 
patients, the number of positive nodes harvested was significantly 
a. b. c. 
Fig. 17: Contingency plots of normalized frequency for a) the ypT stage, b) the ypN stage and, c)the AJCC stage 
for patients that underwent neoadjuvant treatment and surgery 
 
 
47 
 
higher in younger patients (15.6% with >3 positive nodes harvested), 
i.e. higher percentage of N2 disease, as compared to the older 
cohorts (8.7%) with a p-value of 0.016*. The median number of lymph 
nodes harvested in the younger group was 10 and those among the 
older was 7. The median pathologically positive nodes retrieved in the 
younger group was 4 and in the older group was 3 nodes. Of the 
patients who underwent curative surgery there were 35 patients with 
complete pathological response. This consisted of 10 younger and 25 
older patients and as seen in Fig. 17c comprising of about 11% of the 
total candidates that underwent surgery and is similar across of the 
two age groups in spite of the more aggressive form of the disease in 
younger patients. (the numbers being very small, hence no statistical 
analysis deemed worthwhile). 
The cases of recurrence following surgery was also similar in the two 
groups (Fig. 18a) the difference was statistically insignificant with a p-
value of 0.52. The recurrence rates were 28.5% and 25.7% in the 
younger and older patients respectively. The local recurrence rates 
were more frequent in the young and this trend towards higher local 
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recurrence in < 40 age group is due to the higher number of APRs in 
the young.  
Fig. 18: Contingency plots comaring a) frequency of recurracne and b)site of recurrance across age 
groups 
a. b. 
 
 
49 
 
 6.8 Overall Survival (OS) and Disease Free Survival (DFS) 
Of the 532 patients who were treated, 320 completed treatment while 
the remaining 212 patients defaulted with 156 of these defaulting after 
neoadjuvant therapy. The 5 year overall survival and the disease free 
survival analysis of the patients less than 40 compared to those more 
than 40 and also across each 10 year age groups did not assume 
statistical significance (Fig. 19). However there is a trend showing 
Fig. 19: Comparison of overall survial and disease free survival for patients that received complete treatment a) 
for patients ≤ 40 and >40 years, and  b) patients  in the following subcategories: < 30, 30-40, 40-50, ≥50 
a. 
b. 
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poorer 5 year survival (66% alive at end of 5 years) and poorer 
disease free survival (54% disease free at end of 5years) in the age 
group 30-40 compared to the rest.  
This trend towards poorer OS and DFS is also seen in the less than 
40 age group though not statistically significant. The only age cut off 
showing trend towards difference in survival was 40 years . In the 
Fig. 20: Comparison of overall survial and disease free survival for a)Stage 2 and, b) Stage 3 patients that received 
complete treatment for patients ≤ 40 and >40 years. 
a. 
b. 
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other age cut offs i.e. 30, 35, 45 etc  the survival patterns seemed to 
be similar. Further subset analysis of the 320 patients was done to 
compare stagewise survival separately of the 229 patients who had 
NACT RT followed by surgery (Fig. 20) and the 91 patients who 
underwent straight surgery (Fig. 21). A trend towards poorer survival 
was again seen in the yp stage III patients in the less than 40 age 
group (with 55% survivors at 5 years compared to 72% survivors at 5 
years in the older group)  though it did not assume statistical 
significance .  
Again in the subset of patients who underwent straight surgery with 
pathological stage II disease, there was statistically significant overall 
Fig. 21: Comparison of overall survial and disease free survival for Stage 2 patients that underwent direct surgery 
for the groups ≤ 40 and >40 years. 
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survival difference. But this might not be of any clinical relevance due 
to the low number of patients in the less than 40 age group in this 
subset.  
Thus, if patients with distant metastasis were  excluded , no statistical 
difference was observed in the overall survival between the younger 
and older patients with rectal cancer since appropriate treatment 
dictated by stage was delivered.  
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7. Discussion 
The incidence of CRC among the young in Indian population is 
significantly higher compared to the western statistics.  Our study 
shows that as high as 31% (41% less than 45) of the reported rectal 
cancer patients are younger than 40 years of age. Such higher 
incidences are also quoted in studies from other regional centers 
across India [23,24,25,27]. Further molecular and genetic studies are 
needed for the elucidation of novel molecular pathways in the 
pathogenesis of rectal cancer in younger adults as well as to identify 
potential new target agents for better systemic therapy for this group 
of patients. 
Our study demonstrate that rectal cancers in the young vary 
significantly with respect to the histological type, grade and infiltrative 
pattern of growth compared to the older cohorts as witnessed in the 
literature [32,40,41]. The younger patients had a greater incidence of 
obstructive tumors requiring diversion colostomy. Thus the younger 
patients presented with higher clinical stage and hence more 
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frequently underwent neoadjuvant chemoradiation compared to the 
older patients. 
The response to chemoradiation in the young was poorer than the old 
(though not statistically significant) and there was significant rates of 
progression of disease during treatment among the young. 
The type of surgery performed was related to the distance of tumor 
from  anal verge and more frequent sphincter sparing procedures 
were done in the latter half of the study period (2003-2007). 
Pathological staging showed significantly higher Nodal staging among 
the young with a higher median nodal retrieval (10 nodes for ≤ 40 
years, 7 nodes for > 40 years) and higher median positive nodes (4 
positive nodes for ≤ 40 years, 3 positive nodes for > 40 years). 
The overall recurrence pattern local, regional and systemic was not 
significantly different, but the local recurrence rated were twice more 
frequent in the young due to  the more distal tumors , more number of 
APR done and advanced cT stage . 
Our findings for the incidence of rectal cancer in young concur with 
other epidemiological studies from various regional cancer centers in 
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India. We therefore cannot duplicate western screening strategies that 
advice colonoscopy only after the age of 50 years to bring down the 
mortality in rectal cancer. Our emphasis, instead, should be on the 
early detection of rectal cancer through awareness programs among 
the public, and more so among the medical fraternity. There are 
several reasons for delayed detection of rectal cancer in younger 
adults. 
 Ignorance in the public and the medical community about such a 
higher incidence of rectal cancer among the young. 
  Reluctance on the part of patients to approach qualified medical 
professionals and attribution of symptoms to hemorrhoids by the 
patient and the physician  
 Lack of training and reluctance  among the peripheral medical 
professionals and health workers about the value of proper 
digital rectal examination to detect cancer  
Educating the nonsurgical medical health professional about the 
importance of digital rectal examination (DRE) would do a lot towards 
early detection of cases. In fact, our study show that irrespective of the 
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age, around 80% of all rectal cancers were within 6cm from the anal 
verge which can be easily detected by DRE.  
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8. Conclusion 
If familial cancer of rectum in the young are excluded, the outcome of 
treatment in the young is comparable to the older population. Hence 
the pessimism associated with young rectal cancer patients must be 
shed away and they should be treated as any other patient 
appropriate for the stage. 
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